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Androgens regulate biological pathways to promote proliferation, differentiation, and sur-
vival of benign and malignant prostate tissue. Androgen receptor (AR) targeted therapies
exploit this dependence and are used in advanced prostate cancer to control disease
progression. Contemporary treatment regimens involve sequential use of inhibitors of
androgen synthesis or AR function. Although targeting the androgen axis has clear ther-
apeutic benefit, its effectiveness is temporary, as prostate tumor cells adapt to survive
and grow. The removal of androgens (androgen deprivation) has been shown to activate
both epithelial-to-mesenchymal transition (EMT) and neuroendocrine transdifferentiation
(NEtD) programs. EMT has established roles in promoting biological phenotypes associ-
ated with tumor progression (migration/invasion, tumor cell survival, cancer stem cell-like
properties, resistance to radiation and chemotherapy) in multiple human cancer types.
NEtD in prostate cancer is associated with resistance to therapy, visceral metastasis, and
aggressive disease. Thus, activation of these programs via inhibition of the androgen axis
provides a mechanism by which tumor cells can adapt to promote disease recurrence and
progression. Brachyury, Axl, MEK, and Aurora kinase A are molecular drivers of these pro-
grams, and inhibitors are currently in clinical trials to determine therapeutic applications.
Understanding tumor cell plasticity will be important in further defining the rational use
of androgen-targeted therapies clinically and provides an opportunity for intervention to
prolong survival of men with metastatic prostate cancer.
Keywords: prostate cancer, epithelial-to-mesenchymal transition, neuroendocrine, androgen deprivation therapy,
castrate resistant, tumor cell plasticity, brachyury, Axl
INTRODUCTION
Prostate cancer is the most prevalent malignancy in men, and
ranks second as the cause of cancer-related deaths in the devel-
oped world (1, 2). Advanced prostate cancer is initially treated
with androgen deprivation therapy (ADT) and subsequently with
newer generation androgen-targeted therapies (ATT), approaches
which rely on the central role of androgens in tumor develop-
ment and growth. In the majority of patients, castrate resistant
prostate cancer (CRPC) develops and tumor progression occurs
despite treatment. The development of agents that more effec-
tively block androgen receptor (AR) activity, such as enzalutamide
and abiraterone, has greatly enhanced the clinical armamentarium
and extended survival (3–6). Nonetheless, advanced prostate can-
cer remains incurable. Tumor cell plasticity induced by androgen
deprivation may play a critical role in disease progression, and
potentially provides an additional opportunity to further improve
cancer control.
PROGRESSION TO CASTRATE RESISTANCE
While the exact mechanisms underlying the development of CRPC
are not yet known, it arises when cancer cells can either main-
tain AR signaling in the absence of normal levels of ligand or no
longer require activation of this pathway for survival and pro-
liferation. There are a number of mechanisms that can produce
this outcome, including altered functionality of the AR due to
genomic events, resulting in either promiscuous (7, 8), constitu-
tively activated (9, 10), or hypersensitive (11, 12) states; intrapro-
static production of androgens by tumor cells themselves (13); and
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altered growth factor and/or microenvironment signaling (14–18).
Despite the development of multiple strategies that effectively tar-
get the androgen axis, disease progression is inevitable. This is
underpinned by the accumulation of further genomic abnormali-
ties, outgrowth of different clonal populations of tumor cells, and
the adaptive response of cancer cells to therapy. In this review,
we focus on adaptive changes induced by therapy, specifically
epithelial-to-mesenchymal plasticity (EMP) and neuroendocrine
transdifferentiation (NEtD), which may contribute to the devel-
opment of advanced disease (Figure 1). A better understanding of
these processes will contribute to the development of new ther-
apeutic strategies that may potentially enhance the efficacy of
androgen-targeted agents and delay disease progression.
EPITHELIAL-TO-MESENCHYMAL PLASTICITY
Epithelial-to-mesenchymal transition (EMT) is a process by which
adherent, polar cells with an otherwise epithelial phenotype
develop more migratory and invasive properties through altered
gene expression (19–23). Both EMT and the related process
mesenchymal-to-epithelial transition are physiological mecha-
nisms important in development and tissue repair. However, when
differentiated epithelium begins to display mesenchymal charac-
teristics it is often a sign of disease progression in cancers (19,
24–27). EMT is commonly characterized by the loss of epithelial
markers (typically E-cadherin, epithelial cytokeratins, and desmo-
somes), and gain of mesenchymal markers (such as N-cadherin,
vimentin, and fibronectin) and transcriptional repressors of E-
cadherin (Twist1, Snai1, Snai2, Zeb1, Zeb2) (20, 21). EMT has
been associated with advanced prostate cancer, and correlated
with aggressive behavior and therapy resistance in primary tumors
(17, 28–30).
NEUROENDOCRINE TRANSDIFFERENTIATION
While men may present with prostate cancer demonstrating
various neuroendocrine features (31), the prevalence of
neuroendocrine differentiation increases following ADT and in
CRPC (32–37). These cells not only express neuropeptides, rem-
iniscent of the normal NE cells of the prostate, but also proteins
that are characteristic of prostate epithelial cells [such as prosta-
tic acid phosphatase cytokeratin 8/18 and/or epithelial adhesion
molecules and proliferation markers (38, 39)], while AR expres-
sion is typically absent or low (40). Importantly, the number of
NE-like prostate cancer cells is positively associated with the dura-
tion of hormone deprivation therapy (32–34). There are several
hypotheses for the origin of NE-like prostate cancer cells. It has
been postulated that NE-like cancer cells can arise during dis-
ease progression from NE cells of the prostate (41). However, the
observation that genetic aberrations are common to both the ade-
nocarcinoma and NE-like cells (42–45) suggests that this is not
likely to be a common mechanism. An alternative explanation is
that a common progenitor prostate cancer stem cell gives rise to
both the NE-like and adenocarcinoma components and both these
components continue to evolve and respond to selective pressures
in parallel (42, 44, 46, 47). In contrast, NEtD is a process that can
enable prostatic adenocarcinoma cells to gain NE characteristics
without relying on genetic divergence. NEtD can occur after pro-
longed androgen deprivation, and has recently been reported in
a patient derived xenograft (48). This mechanism would poten-
tially enable tumor cells to reduce ATT-induced apoptosis and
thus provide an adaptive pathway that would contribute to the
development of CRPC (41).
ANDROGENS SUPPRESS NEUROENDOCRINE
TRANSDIFFERENTIATION
Evidence of NEtD has been observed in both in vitro and in vivo
studies. LNCaP cells, an androgen dependent prostate cancer cell
line derived from a lymph node metastasis, undergo NEtD when
exposed to media lacking androgens (39, 49–51). In low-androgen
conditions, LNCaP cells take on an altered elongated neuron-like
FIGURE 1 | Inhibition of androgen receptor (AR) signaling using
androgen-targeted therapies (ATT) induces adaptive responses
including epithelial–mesenchymal transition (EMT) and
neuroendocrine transdifferentiation (NEtD) in prostate cancer cells.
These phenotypes are associated with CRPC (castrate resistance prostate
cancer). Inhibition of plasticity drivers Brachyury, Axl, MEK, and Aurora
kinase A provide potential mechanisms to reduce the induction of the EMT
and/or NEtD phenotypes.
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phenotype, gain cytoplasmic secretory granules, and undergo
growth arrest. This is accompanied by an increase in expression of
NE markers and a decrease in AR and PSA levels. This transdif-
ferentiation is reversible with the addition of androgens (DHT) to
the media, an observation consistent with the identical allelic pro-
files of NEtD LNCaP and parental LNCaP cells. Silencing of the AR
using siRNA also induces NEtD in LNCaP cells, suggesting that AR
signaling suppresses NEtD (52). In vivo studies also provide sup-
port for the NEtD model. Castration of nude mice bearing prostate
cancer xenografts LNCaP, PC-295, CWR22, and PC-310 increased
the number of tumor cells expressing NE markers, consistent with
induction of NEtD (53–56). Furthermore, implantation of pri-
mary patient tumor tissues from a population of adenocarcinoma
cells implanted under the renal capsule of castrated mice appear
to undergo an NEtD en masse as an adaptive response (48).
THERAPY-INDUCED EMT
There is accumulating evidence supporting that ADT may induce
an EMT, and that this is particularly prominent with the newer
generation ATT. ADT has been associated with an increase in the
expression of mesenchymal markers N-cadherin, vimentin, Zeb1,
Twist1, and Snai2, with a concomitant loss of E-cadherin in patient
derived xenografts and clinical prostate tumors (17, 57–59). Tra-
ditionally, investigations have primarily focused on the effects of
targeting AR signaling in prostate cancer cells; however, ADT/ATT
is not specific to tumor cells alone. Recent reports demonstrate
significant effects of ADT/ATT on the tumor microenvironment,
including stromal and immune cells (15, 18, 60). For instance,
elevated numbers of tumor associated macrophages have been
reported in men undergoing ADT (60), and these cells have been
shown to promote local invasion and metastatic dissemination of
tumor cells in response to ADT (18, 57–60). Hence, the implica-
tions of targeting the androgen axis and its effect on the multiple
cell types comprising the tumor microenvironment needs to be
assessed when considering therapeutic interventions.
THERAPY-INDUCED EMT AND NEUROENDOCRINE
TRANSDIFFERENTIATION AS CLINICAL TARGETS
Therapeutically targeting regulators of EMP/NEtD is an attrac-
tive concept that has recently matured to clinical trials (Figure 1).
Brachyury is a transcription factor required for the developmen-
tal EMT that generates mesoderm by converting epithelial cells
into migratory mesenchymal cells (61). In tumor cells, includ-
ing prostate cancer, Brachyury also induces EMT and an invasive
phenotype (62–65). Furthermore, Brachyury is overexpressed at
both the transcript and protein level in clinical prostate cancer
specimens, and nuclear expression is associated with metastasis
(66). While the regulation of Brachyury by androgen-targeted
therapies has not been addressed, Brachyury motifs were highly
enriched in AR bound promoters when LAPC-4 cells were grown
in the presence of AR antagonist flutamide (67). Furthermore,
in silico bioinformatic analysis using transcriptional profiles from
clinical prostate cancer specimens and clustering Brachyury co-
expressed genes by functional role/signaling pathways demon-
strated an enrichment for regulation of neuron differentiation
and nervous system development (68). An inverse relationship
between Brachyury and E-cadherin expression, with a concomi-
tant positive correlation of Brachyury with EMT promoting genes
FN1, Snai1, IL8, and TGF-β was also observed. Thus, we hypothe-
size that targeting Brachyury in the context of ATT may modulate
the emergence of both a neuroendocrine phenotype and EMP
by preventing, for example, the induction of Brachyury medi-
ated release of migration/invasion promoting soluble factors into
the tumor microenvironment (62, 68, 69). GI-6301 (Tarmogen)
is a Brachyury vaccine (70) currently in Phase I clinical trial in
patients with metastatic or unresectable locally recurrent cancers
who have failed previous therapy or have no further therapeutic
options (NCT01519817). Recent assessment of data from patients
with advanced chordoma in this trial demonstrated safety and a
confirmed partial response (71), and data from the larger cohort
are eagerly awaited.
The receptor tyrosine kinase Axl is implicated in the Snai1-,
Snai2-, IL6-, and STAT3-mediated activation of EMT (72, 73)
as well as the metastasis promoting AKT/NF-κB and AKT/Snai2
pathways (73, 74) in multiple cancer types. Targeting Axl has
shown promise in preclinical models of cancer progression (75–
77), and clinical trials are currently underway. BGB324 is a small
molecule inhibitor of the Axl receptor tyrosine kinase developed to
block EMT with the goal of inhibiting drug-resistance and metas-
tasis. Recent Phase Ia data have demonstrated BGB324 to be safe
and well tolerated, and Phase Ib studies commenced in non-small
cell lung cancer and acute myeloid leukemia in 2014. Cabozanti-
nib is another tyrosine kinase inhibitor targeting Axl, as well as
EMT promoting kinases VEGFR2, RET, KIT, FLT-1/3/4, c-MET,
and Tie-2 (78–80). Clinically significant regression of metasta-
tic tumors in CRPC patients was achieved with cabozantinib
treatment in a Phase II trial (81). Of course the precise molec-
ular mechanism underpinning this efficacy is not clear and likely
involves inhibition of multiple tyrosine kinases in several cell types.
Trials investigating whether cabozantinib is a useful addition to
ADT in the control of prostate cancer are currently underway
(NCT01630590).
MEK inhibitors may also be useful in managing therapy-
induced EMP/NEtD. In vitro, MEK inhibitor PD98059 blocked
the acquisition of NE-like morphology and prevented the increase
in NSE levels usually observed in LNCaP-C33 cells induced to
undergo NEtD by androgen-depletion (82). Ectopic expression of
constitutively active AR in LNCaP cells inhibited RAF/MEK/ERK-
induced NSE expression (83), demonstrating the central regu-
latory role of AR in constraining the emergence of this pheno-
type. Furthermore, the RAF/MEK/ERK pathway has been shown
to be necessary for the induction of Twist1, Snai1, and N-
cadherin in multiple cancer models (84, 85). A neoadjuvant trial
examining the effect of short-term MEK inhibition (trametinib)
prior to radical prostatectomy in the context of ADT on mark-
ers of EMT (N-cadherin, vimentin) has recently commenced
(NCT01990196).
Finally, Aurora kinase A (AURKA) inhibitors may also be effec-
tive in inhibiting ATT-induced EMP/NEtD as they suppress both
EMT and NEtD in vitro and in vivo (86, 87). In cancer cells,
AURKA has been demonstrated to play an important role in the
genesis of a more mesenchymal phenotype via down-regulation
of E-cadherin and up-regulation of vimentin (88). Clinical trials
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examining the role of the inhibitors in prostate cancer are currently
ongoing (NCT01799278, NCT01094288).
Despite independent lines of evidence implicating key factors
in both EMT and NEtD, the functional and molecular relation-
ship between these states in prostate cancer has not been exten-
sively explored. McKeithen et al. (89) have demonstrated that the
well-established EMT-inducing transcription factor Snai1 induced
both EMT and NEtD in LNCaP cells as defined by morphology
and marker expression. However, as the data are mostly presented
as analyses of bulk populations of cells, it is not possible to deter-
mine whether EMT and NEtD phenotypes are co-expressed within
individual cells, and are thus intimately linked, or whether these
transdifferentiation processes are independent of each other and
become activated by influences such as neighboring cells, local
microenvironmental cues, or cell intrinsic factors.
CONCLUDING REMARKS
Multiple factors are clearly involved in the progression to CRPC
during treatment with ATT. Studies over the past two decades
have associated blockade of the androgen axis with the increased
prevalence of neuroendocrine prostate cancer. These observations,
in combination with recent reports of androgen deprivation mod-
ulating EMP, suggest novel strategies for therapeutic intervention.
Further studies will be required to determine whether these adap-
tive response pathways have a functional role in the progression to
CRPC or are simply a consequence of removing the differentiation
pressure imposed by active androgen signaling on prostate cells.
Moreover, revealing if and how these plasticity pathways inter-
sect in the androgen-targeted environment will be an intriguing
area for future research. Improved understanding of the molecu-
lar pathways underlying the adaptive responses to ATT provides
opportunities to investigate whether targeted inhibition of these
pathways will delay tumor progression and thus improve outcomes
for men with prostate cancer.
ACKNOWLEDGMENTS
The authors’ research is supported by the Movember Founda-
tion and the Prostate Cancer Foundation of Australia through
a Movember Revolutionary Team Award. Brett G. Hollier is
supported by a Queensland Government Smart Futures Fund
Fellowship.
REFERENCES
1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin (2010)
60:277–300. doi:10.3322/caac.20073
2. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin (2014)
64:9–29. doi:10.3322/caac.21208
3. Dreicer R, MacLean D, Suri A, Stadler WM, Shevrin D, Hart L, et al. Phase
I/II trial of orteronel (TAK-700) – an investigational 17,20-lyase inhibitor – in
patients with metastatic castration-resistant prostate cancer. Clin Cancer Res
(2014) 20:1335–44. doi:10.1158/1078-0432.CCR-13-2436
4. Joseph JD, Lu N, Qian J, Sensintaffar J, Shao G, Brigham D, et al. A clinically
relevant androgen receptor mutation confers resistance to second-generation
antiandrogens enzalutamide and ARN-509. Cancer Discov (2013) 3:1020–9.
doi:10.1158/2159-8290.CD-13-0226
5. Rathkopf DE, Morris MJ, Fox JJ, Danila DC, Slovin SF, Hager JH, et al. Phase I
study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant
prostate cancer. J Clin Oncol (2013) 31:3525–30. doi:10.1200/JCO.2013.50.1684
6. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast
T, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced,
relapsing, and castration-resistant prostate cancer. Eur Urol (2014) 65:467–79.
doi:10.1016/j.eururo.2013.11.002
7. Fujimoto N, Miyamoto H, Mizokami A, Harada S, Nomura M, Ueta Y,
et al. Prostate cancer cells increase androgen sensitivity by increase in nuclear
androgen receptor and androgen receptor coactivators; a possible mechanism
of hormone-resistance of prostate cancer cells. Cancer Invest (2007) 25:32–7.
doi:10.1080/07357900601130698
8. Tsao CK, Galsky MD, Small AC, Yee T, Oh WK. Targeting the androgen receptor
signalling axis in castration-resistant prostate cancer (CRPC). BJU Int (2012)
110:1580–8. doi:10.1111/j.1464-410X.2012.11445.x
9. Attar RM, Takimoto CH, Gottardis MM. Castration-resistant prostate cancer:
locking up the molecular escape routes. Clin Cancer Res (2009) 15:3251–5.
doi:10.1158/1078-0432.CCR-08-1171
10. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ. Splicing of a
novel androgen receptor exon generates a constitutively active androgen receptor
that mediates prostate cancer therapy resistance. Cancer Res (2008) 68:5469–77.
doi:10.1158/0008-5472.CAN-08-0594
11. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, et al.
In vivo amplification of the androgen receptor gene and progression of human
prostate cancer. Nat Genet (1995) 9:401–6. doi:10.1038/ng0495-401
12. Waltering KK, Helenius MA, Sahu B, Manni V, Linja MJ, Janne OA, et al.
Increased expression of androgen receptor sensitizes prostate cancer cells to
low levels of androgens. Cancer Res (2009) 69:8141–9. doi:10.1158/0008-5472.
CAN-09-0919
13. Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, et al. Andro-
gen levels increase by intratumoral de novo steroidogenesis during progres-
sion of castration-resistant prostate cancer. Cancer Res (2008) 68:6407–15.
doi:10.1158/0008-5472.CAN-07-5997
14. Lai JJ, Lai KP, Chuang KH, Chang P, Yu IC, Lin WJ, et al. Monocyte/macrophage
androgen receptor suppresses cutaneous wound healing in mice by enhanc-
ing local TNF-alpha expression. J Clin Invest (2009) 119:3739–51. doi:10.1172/
JCI39335
15. Loberg RD, Ying C, Craig M, Yan L, Snyder LA, Pienta KJ. CCL2 as an impor-
tant mediator of prostate cancer growth in vivo through the regulation of
macrophage infiltration. Neoplasia (2007) 9:556–62. doi:10.1593/neo.07307
16. Lubik AA, Gunter JH, Hollier BG, Ettinger S, Fazli L, Stylianou N, et al. IGF2
increases de novo steroidogenesis in prostate cancer cells. Endocr Relat Cancer
(2013) 20:173–86. doi:10.1530/ERC-12-0250
17. Sun Y, Wang BE, Leong KG, Yue P, Li L, Jhunjhunwala S, et al. Androgen depri-
vation causes epithelial-mesenchymal transition in the prostate: implications
for androgen-deprivation therapy. Cancer Res (2012) 72:527–36. doi:10.1158/
0008-5472.CAN-11-3004
18. Zhu P, Baek SH, Bourk EM, Ohgi KA, Garcia-Bassets I, Sanjo H, et al.
Macrophage/cancer cell interactions mediate hormone resistance by a nuclear
receptor derepression pathway. Cell (2006) 124:615–29. doi:10.1016/j.cell.2005.
12.032
19. Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, Kasimir-Bauer S. Stem cell
and epithelial-mesenchymal transition markers are frequently overexpressed in
circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res
(2009) 11:R46. doi:10.1186/bcr2333
20. Chaffer CL, Thompson EW, Williams ED. Mesenchymal to epithelial tran-
sition in development and disease. Cells Tissues Organs (2007) 185:7–19.
doi:10.1159/000101298
21. Hugo H, Ackland ML, Blick T, Lawrence MG, Clements JA, Williams ED, et al.
Epithelial-mesenchymal and mesenchymal-epithelial transitions in carcinoma
progression. J Cell Physiol (2007) 213:374–83. doi:10.1002/jcp.21223
22. Said NABM, Williams ED. Remodelling the malignant phenotype: impact of
EMT. Drug Discov Today Dis Models (2009) 6:21–5. doi:10.1016/j.ddmod.2008.
12.002
23. Thompson EW,Williams ED. EMT and MET in carcinoma-clinical observations,
regulatory pathways and new models. Clin Exp Metastasis (2008) 25:591–2.
doi:10.1007/s10585-008-9189-8
24. Bhangu A, Wood G, Mirnezami A, Darzi A, Tekkis P, Goldin R. Epithelial mes-
enchymal transition in colorectal cancer: seminal role in promoting disease pro-
gression and resistance to neoadjuvant therapy. Surg Oncol (2012) 21:316–23.
doi:10.1016/j.suronc.2012.08.003
25. Ding W, Nowakowski GS, Knox TR, Boysen JC, Maas ML, Schwager SM, et al.
Bi-directional activation between mesenchymal stem cells and CLL B-cells:
Frontiers in Oncology | Molecular and Cellular Oncology December 2014 | Volume 4 | Article 370 | 4
Nouri et al. Therapy-induced tumor cell plasticity
implication for CLL disease progression. Br J Haematol (2009) 147:471–83.
doi:10.1111/j.1365-2141.2009.07868.x
26. Kim SH, Yu MA, Ryu ES, Jang YH, Kang DH. Indoxyl sulfate-induced epithelial-
to-mesenchymal transition and apoptosis of renal tubular cells as novel mecha-
nisms of progression of renal disease. Lab Invest (2012) 92:488–98. doi:10.1038/
labinvest.2011.194
27. Turley EA, Veiseh M, Radisky DC, Bissell MJ. Mechanisms of disease: epithelial-
mesenchymal transition-does cellular plasticity fuel neoplastic progression? Nat
Clin Pract Oncol (2008) 5:280–90. doi:10.1038/ncponc1089
28. Das R, Gregory PA, Hollier BG, Tilley WD, Selth LA. Epithelial plasticity in
prostate cancer: principles and clinical perspectives. Trends Mol Med (2014)
20(11):643–51. doi:10.1016/j.molmed.2014.09.004
29. Marin-Aguilera M, Codony-Servat J, Reig O, Lozano JJ, Fernandez PL, Pereira
MV, et al. Epithelial-to-mesenchymal transition mediates docetaxel resistance
and high risk of relapse in prostate cancer. Mol Cancer Ther (2014) 13:1270–84.
doi:10.1158/1535-7163.MCT-13-0775
30. Ren D, Wang M, Guo W, Huang S, Wang Z, Zhao X, et al. Double-negative
feedback loop between ZEB2 and miR-145 regulates epithelial-mesenchymal
transition and stem cell properties in prostate cancer cells. Cell Tissue Res (2014)
358(3):763–78. doi:10.1007/s00441-014-2001-y
31. Epstein JI, Amin MB, Beltran H, Lotan TL, Mosquera JM, Reuter VE,
et al. Proposed morphologic classification of prostate cancer with neuroen-
docrine differentiation. Am J Surg Pathol (2014) 38:756–67. doi:10.1097/PAS.
0000000000000208
32. Abrahamsson PA, Falkmer S, Falt K, Grimelius L. The course of neuroendocrine
differentiation in prostatic carcinomas. An immunohistochemical study testing
chromogranin A as an “endocrine marker”. Pathol Res Pract (1989) 185:373–80.
doi:10.1016/s0344-0338(89)80016-0
33. Hirano D, Okada Y, Minei S, Takimoto Y, Nemoto N. Neuroendocrine differen-
tiation in hormone refractory prostate cancer following androgen deprivation
therapy. Eur Urol (2004) 45:586–92. doi:10.1016/j.eururo.2003.11.032
34. Ito T, Yamamoto S, Ohno Y, Namiki K, Aizawa T, Akiyama A, et al. Up-
regulation of neuroendocrine differentiation in prostate cancer after andro-
gen deprivation therapy, degree and androgen independence. Oncol Rep (2001)
8:1221.
35. Jiborn T, Bjartell A, Abrahamsson PA. Neuroendocrine differentiation in
prostatic carcinoma during hormonal treatment. Urology (1998) 51:585–9.
doi:10.1016/S0090-4295(97)00684-5
36. di Sant’Agnese PA. Neuroendocrine differentiation in carcinoma of
the prostate. Diagnostic, prognostic, and therapeutic implications. Can-
cer (1992) 70:254–68. doi:10.1002/1097-0142(19920701)70:1+<254::AID-
CNCR2820701312>3.0.CO;2-E
37. Wafa LA, Palmer J, Fazli L, Hurtado-Coll A, Bell RH, Nelson CC, et al. Com-
prehensive expression analysis of L-DOPA decarboxylase and established neu-
roendocrine markers in neoadjuvant hormone-treated versus varying Gleason
grade prostate tumors. Hum Pathol (2007) 38:161–70. doi:10.1016/j.humpath.
2006.07.003
38. Vashchenko N, Abrahamsson PA. Neuroendocrine differentiation in prostate
cancer: implications for new treatment modalities. Eur Urol (2005) 47:147–55.
doi:10.1016/j.eururo.2004.09.007
39. Yuan T-C, Veeramani S, Lin F-F, Kondrikou D, Zelivianski S, Igawa T, et al.
Androgen deprivation induces human prostate epithelial neuroendocrine dif-
ferentiation of androgen-sensitive LNCaP cells. Endocr Relat Cancer (2006)
13:151–67. doi:10.1677/erc.1.01043
40. Huang J, Yao JL, di Sant’Agnese PA, Yang Q, Bourne PA, Na Y. Immunohisto-
chemical characterization of neuroendocrine cells in prostate cancer. Prostate
(2006) 66:1399–406. doi:10.1002/pros.20434
41. Beltran H, Tomlins S, Aparicio A, Arora V, Rickman D, Ayala G, et al. Aggres-
sive variants of castration-resistant prostate cancer. Clin Cancer Res (2014)
20:2846–50. doi:10.1158/1078-0432.ccr-13-3309
42. Hansel DE, Nakayama M, Luo J, Abukhdeir AM, Park BH, Bieberich CJ, et al.
Shared TP53 gene mutation in morphologically and phenotypically distinct
concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma
of the prostate. Prostate (2009) 69:603–9. doi:10.1002/pros.20910
43. Lotan TL, Gupta NS, Wang W, Toubaji A, Haffner MC, Chaux A, et al. ERG gene
rearrangements are common in prostatic small cell carcinomas. Mod Pathol
(2011) 24:820–8. doi:10.1038/modpathol.2011.7
44. Palmgren JS, Karavadia SS, Wakefield MR. Unusual and underappreciated: small
cell carcinoma of the prostate. Semin Oncol (2007) 34:22–9. doi:10.1053/j.
seminoncol.2006.10.026
45. Williamson SR, Zhang S, Yao JL, Huang J, Lopez-Beltran A, Shen S, et al. ERG-
TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma
and prostatic small cell carcinoma and absent in small cell carcinoma of the
urinary bladder: evidence supporting monoclonal origin. Mod Pathol (2011)
24:1120–7. doi:10.1038/modpathol.2011.56
46. Bonkhoff H, Remberger K. Differentiation pathways and histogenetic
aspects of normal and abnormal prostatic growth: a stem cell model.
Prostate (1996) 28:98–106. doi:10.1002/(SICI)1097-0045(199602)28:2<98:
AID-PROS4>3.0.CO;2-J
47. Bonkhoff H, Wernert N, Dhom G, Remberger K. Relation of endocrine-
paracrine cells to cell proliferation in normal, hyperplastic, and neoplastic
human prostate. Prostate (1991) 19:91–8. doi:10.1002/pros.2990190202
48. Lin D, Wyatt AW, Xue H, Wang Y, Dong X, Haegert A, et al. High fidelity
patient-derived xenografts for accelerating prostate cancer discovery and drug
development. Cancer Res (2014) 74:1272–83. doi:10.1158/0008-5472.CAN-13-
2921-T
49. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, et al.
LNCaP model of human prostatic carcinoma. Cancer Res (1983) 43:1809–18.
50. Shen R, Dorai T, Szaboles M, Katz AE, Olsson CA, Buttyan R. Transdif-
ferentiation of cultured human prostate cancer cells to a neuroendocrine
cell phenotype in a hormone-depleted medium. Urol Oncol (1997) 3:67–75.
doi:10.1016/S1078-1439(97)00039-2
51. Zelivianski S,Verni M, Moore C, Kondrikov D, Taylor R, Lin M-F. Multipathways
for transdifferentiation of human prostate cancer cells into neuroendocrine-
like phenotype. Biochim Biophys Acta (2001) 1539:28–43. doi:10.1016/S0167-
4889(01)00087-8
52. Wright ME, Tsai M-J, Aebersold R. Androgen receptor represses the neuroen-
docrine transdifferentiation process in prostate cancer cells. Mol Endocrinol
(2003) 17:1726–37. doi:10.1210/me.2003-0031
53. Burchardt T, Burchardt M, Chen MW, Cao Y, de la Taille A, Shabsigh A, et al.
Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype
in vitro and in vivo. J Urol (1999) 162:1800–5. doi:10.1016/S0022-5347(05)
68241-9
54. Jongsma J, Oomen MH, Noordzij MA, Van Weerden WM, Martens GJM, van
der Kwast TH, et al. Kinetics of neuroendocrine differentiation in an androgen-
dependent human prostate xenograft model. Am J Pathol (1999) 154:543–51.
doi:10.1016/S0002-9440(10)65300-X
55. Huss WJ, Gregory CW, Smith GJ. Neuroendocrine cell differentiation in the
CWR22 human prostate cancer xenograft: association with tumor cell prolifer-
ation prior to recurrence. Prostate (2004) 60:91–7. doi:10.1002/pros.20032
56. Jongsma J, Oomen MH, Noordzij MA, Van Weerden WM, Martens GJ, van
der Kwast TH, et al. Androgen deprivation of the PC-310 human prostate can-
cer model system induces neuroendocrine differentiation. Cancer Res (2000)
60:741–8.
57. Izumi K, Fang LY, Mizokami A, Namiki M, Li L, Lin WJ, et al. Targeting the
androgen receptor with siRNA promotes prostate cancer metastasis through
enhanced macrophage recruitment via CCL2/CCR2-induced STAT3 activation.
EMBOMol Med (2013) 5:1383–401. doi:10.1002/emmm.201202367
58. Lin TH, Izumi K, Lee SO, Lin WJ, Yeh S, Chang C. Anti-androgen receptor ASC-
J9 versus anti-androgens MDV3100 (enzalutamide) or casodex (bicalutamide)
leads to opposite effects on prostate cancer metastasis via differential modu-
lation of macrophage infiltration and STAT3-CCL2 signaling. Cell Death Dis
(2013) 4:e764. doi:10.1038/cddis.2013.270
59. Lin TH, Lee SO, Niu Y, Xu D, Liang L, Li L, et al. Differential andro-
gen deprivation therapies with anti-androgens casodex/bicalutamide or
MDV3100/enzalutamide versus anti-androgen receptor ASC-J9(R) lead to pro-
motion versus suppression of prostate cancer metastasis. J Biol Chem (2013)
288:19359–69. doi:10.1074/jbc.M113.477216
60. Gannon PO, Poisson AO, Delvoye N, Lapointe R, Mes-Masson AM, Saad F.
Characterization of the intra-prostatic immune cell infiltration in androgen-
deprived prostate cancer patients. J Immunol Methods (2009) 348:9–17. doi:10.
1016/j.jim.2009.06.004
61. Yamada T. Caudalization by the amphibian organizer: Brachyury, convergent
extension and retinoic acid. Development (1994) 120:3051–62.
www.frontiersin.org December 2014 | Volume 4 | Article 370 | 5
Nouri et al. Therapy-induced tumor cell plasticity
62. Fernando RI, Litzinger M, Trono P, Hamilton DH, Schlom J, Palena C. The T-box
transcription factor Brachyury promotes epithelial-mesenchymal transition in
human tumor cells. J Clin Invest (2010) 120:533–44. doi:10.1172/JCI38379
63. Imajyo I, Sugiura T, Kobayashi Y, Shimoda M, Ishii K, Akimoto N, et al. T-
box transcription factor Brachyury expression is correlated with epithelial-
mesenchymal transition and lymph node metastasis in oral squamous cell car-
cinoma. Int J Oncol (2012) 41:1985–95. doi:10.3892/ijo.2012.1673
64. Roselli M, Fernando RI, Guadagni F, Spila A, Alessandroni J, Palmirotta R, et al.
Brachyury, a driver of the epithelial-mesenchymal transition, is overexpressed in
human lung tumors: an opportunity for novel interventions against lung cancer.
Clin Cancer Res (2012) 18:3868–79. doi:10.1158/1078-0432.CCR-11-3211
65. Shimoda M, Sugiura T, Imajyo I, Ishii K, Chigita S, Seki K, et al. The T-box
transcription factor Brachyury regulates epithelial-mesenchymal transition in
association with cancer stem-like cells in adenoid cystic carcinoma cells. BMC
Cancer (2012) 12:377. doi:10.1186/1471-2407-12-377
66. Thoma C. Prostate cancer: Brachyury – a biomarker for progression and prog-
nosis? Nat Rev Urol (2014) 11:485. doi:10.1038/nrurol.2014.184
67. Perets R, Kaplan T, Stein I, Hidas G, Tayeb S, Avraham E, et al. Genome-wide
analysis of androgen receptor targets reveals COUP-TF1 as a novel player in
human prostate cancer. PLoS One (2012) 7:e46467. doi:10.1371/journal.pone.
0046467
68. Pinto F, Pertega-Gomes N, Pereira MS, Vizcaino JR, Monteiro P, Henrique
RM, et al. T-box transcription factor Brachyury is associated with prostate
cancer progression and aggressiveness. Clin Cancer Res (2014) 20:4949–61.
doi:10.1158/1078-0432.CCR-14-0421
69. Fernando RI, Castillo MD, Litzinger M, Hamilton DH, Palena C. IL-8 signal-
ing plays a critical role in the epithelial-mesenchymal transition of human
carcinoma cells. Cancer Res (2011) 71:5296–306. doi:10.1158/0008-5472.CAN-
11-0156
70. Hamilton DH, Litzinger MT, Jales A, Huang B, Fernando RI, Hodge JW, et al.
Immunological targeting of tumor cells undergoing an epithelial-mesenchymal
transition via a recombinant Brachyury-yeast vaccine. Oncotarget (2013)
4:1777–90.
71. Heery CR, Singh H, Jennifer L, Marte JL, Madan RA, O’Sullivan Coyne GH,
et al. NCI experience using yeast-Brachyury vaccine (GI-6301) in patients with
advanced chordoma. J Clin Oncol (2014) 32:abstract 3081.
72. Asiedu MK, Beauchamp-Perez FD, Ingle JN, Behrens MD, Radisky DC, Knutson
KL. Axl induces epithelial-to-mesenchymal transition and regulates the func-
tion of breast cancer stem cells. Oncogene (2014) 33:1316–24. doi:10.1038/onc.
2013.57
73. Paccez JD, Vasques GJ, Correa RG, Vasconcellos JF, Duncan K, Gu X, et al. The
receptor tyrosine kinase Axl is an essential regulator of prostate cancer prolif-
eration and tumor growth and represents a new therapeutic target. Oncogene
(2013) 32:689–98. doi:10.1038/onc.2012.89
74. Li Y, Jia L, Ren D, Liu C, Gong Y, Wang N, et al. Axl mediates tumor invasion
and chemosensitivity through PI3K/Akt signaling pathway and is transcrip-
tionally regulated by slug in breast carcinoma. IUBMB Life (2014) 66:507–18.
doi:10.1002/iub.1285
75. Holland SJ, Pan A, Franci C, Hu Y, Chang B, Li W, et al. R428, a selective
small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs sur-
vival in models of metastatic breast cancer. Cancer Res (2010) 70:1544–54.
doi:10.1158/0008-5472.CAN-09-2997
76. Ye X, Li Y, Stawicki S, Couto S, Eastham-Anderson J, Kallop D, et al. An anti-
Axl monoclonal antibody attenuates xenograft tumor growth and enhances
the effect of multiple anticancer therapies. Oncogene (2010) 29:5254–64.
doi:10.1038/onc.2010.268
77. Zhang YX, Knyazev PG, Cheburkin YV, Sharma K, Knyazev YP, Orfi L, et al. AXL
is a potential target for therapeutic intervention in breast cancer progression.
Cancer Res (2008) 68:1905–15. doi:10.1158/0008-5472.CAN-07-2661
78. Castellone MD, Carlomagno F, Salvatore G, Santoro M. Receptor tyrosine
kinase inhibitors in thyroid cancer. Best Pract Res Clin Endocrinol Metab (2008)
22:1023–38. doi:10.1016/j.beem.2008.09.012
79. Timar J, Dome B. Antiangiogenic drugs and tyrosine kinases. Anticancer Agents
Med Chem (2008) 8:462–9. doi:10.2174/187152008784533035
80. Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, et al. Cabozantinib
(XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metas-
tasis, angiogenesis, and tumor growth. Mol Cancer Ther (2011) 10:2298–308.
doi:10.1158/1535-7163.MCT-11-0264
81. Smith MR, Sweeney CJ, Corn PG, Rathkopf DE, Smith DC, Hussain M,
et al. Cabozantinib in chemotherapy-pretreated metastatic castration-resistant
prostate cancer: results of a phase II nonrandomized expansion study. J Clin
Oncol (2014) 32(30):3391–9. doi:10.1200/JCO.2013.54.5954
82. Zhang XQ, Kondrikov D, Yuan TC, Lin FF, Hansen J, Lin MF. Recep-
tor protein tyrosine phosphatase alpha signaling is involved in andro-
gen depletion-induced neuroendocrine differentiation of androgen-sensitive
LNCaP human prostate cancer cells. Oncogene (2003) 22:6704–16. doi:10.1038/
sj.onc.1206764
83. Hong SK, Kim JH, Lin MF, Park JI. The Raf/MEK/extracellular signal-regulated
kinase 1/2 pathway can mediate growth inhibitory and differentiation signal-
ing via androgen receptor downregulation in prostate cancer cells. Exp Cell Res
(2011) 317:2671–82. doi:10.1016/j.yexcr.2011.08.008
84. Hou CH, Lin FL, Hou SM, Liu JF. Cyr61 promotes epithelial-mesenchymal
transition and tumor metastasis of osteosarcoma by Raf-1/MEK/ERK/Elk-
1/TWIST-1 signaling pathway. Mol Cancer (2014) 13:236. doi:10.1186/1476-
4598-13-236
85. Karamitopoulou E, Zlobec I, Gloor B, Kondi-Pafiti A, Lugli A, Perren A. Loss
of Raf-1 kinase inhibitor protein (RKIP) is strongly associated with high-grade
tumor budding and correlates with an aggressive phenotype in pancreatic ductal
adenocarcinoma (PDAC). J Transl Med (2013) 11:311. doi:10.1186/1479-5876-
11-311
86. Wan XB, Long ZJ, Yan M, Xu J, Xia LP, Liu L, et al. Inhibition of Aurora-A
suppresses epithelial-mesenchymal transition and invasion by downregulating
MAPK in nasopharyngeal carcinoma cells. Carcinogenesis (2008) 29:1930–7.
doi:10.1093/carcin/bgn176
87. Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY, et al. Mol-
ecular characterization of neuroendocrine prostate cancer and identification of
new drug targets. Cancer Discov (2011) 1:487–95. doi:10.1158/2159-8290.cd-
11-0130
88. D’Assoro AB, Liu T, Quatraro C, Amato A, Opyrchal M, Leontovich A, et al. The
mitotic kinase Aurora-A promotes distant metastases by inducing epithelial-to-
mesenchymal transition in ER alpha(+) breast cancer cells. Oncogene (2014)
33:599–610. doi:10.1038/onc.2012.628
89. McKeithen D, Graham T, Chung LW, Odero-Marah V. Snail transcription factor
regulates neuroendocrine differentiation in LNCaP prostate cancer cells.Prostate
(2010) 70:982–92. doi:10.1002/pros.21132
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 23 October 2014; paper pending published: 09 November 2014; accepted: 04
December 2014; published online: 23 December 2014.
Citation: Nouri M, Ratther E, Stylianou N, Nelson CC, Hollier BG and Williams
ED (2014) Androgen-targeted therapy-induced epithelial mesenchymal plasticity and
neuroendocrine transdifferentiation in prostate cancer: an opportunity for intervention.
Front. Oncol. 4:370. doi: 10.3389/fonc.2014.00370
This article was submitted to Molecular and Cellular Oncology, a section of the journal
Frontiers in Oncology.
Copyright © 2014 Nouri, Ratther , Stylianou, Nelson, Hollier andWilliams. This is an
open-access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) or licensor are credited and that the original publica-
tion in this journal is cited, in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not comply with these terms.
Frontiers in Oncology | Molecular and Cellular Oncology December 2014 | Volume 4 | Article 370 | 6
